H. Lundbeck A/S
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From H. Lundbeck A/S
Arcutis's CEO believes that with "a modest investment," the company can generate proof-of-concept data "against a de-risked target in a high-value indication,” Ducentis's preclinical atopic dermatits drug DS-234.
Lack of scale, the need for further funding and problems getting reimbursement for its adrenal insufficiency products left the Wales-headquartered firm vulnerable to a takeover and San Diego's Neurocrine has swooped.
Endo’s woes show no sign of abating, with the US Court of Appeals for the Federal Circuit shooting down its appeal against a finding of non-infringement for two key patents shielding its Vasostrict injectable.
Brexpiprazole could be approved as soon as 2023, and Lundbeck has pledged to support its uptake with investment in its salesforce and direct-to-consumer advertising.
- Other Names / Subsidiaries
- Abide Therapeutics Inc.
- Alder Biopharmaceuticals, Inc.
- Chelsea Therapeutics International, Ltd.
- Lundbeck La Jolla Research Center
- Lundbeck Seattle Biopharmaceuticals
- Ovation Pharmaceuticals, Inc
- Saegis Pharmaceuticals, Inc.